Intellia Therapeutics (NASDAQ:NTLA) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a report released on Saturday.

Several other research analysts also recently commented on NTLA. The Goldman Sachs Group raised their price objective on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a report on Tuesday, April 28th. Citigroup reaffirmed an “outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, April 28th. Wedbush reaffirmed a “neutral” rating and issued a $12.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, May 12th. Wells Fargo & Company raised their price objective on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 3rd. Finally, Leerink Partners set a $35.00 price objective on shares of Intellia Therapeutics in a report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.25.

Intellia Therapeutics Trading Up 4.4%

NTLA opened at $13.67 on Friday. The company has a 50 day moving average of $13.63 and a 200 day moving average of $11.99. The company has a market cap of $1.91 billion, a PE ratio of -3.86 and a beta of 1.93. Intellia Therapeutics has a 12 month low of $6.83 and a 12 month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11. The company had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same period last year, the firm earned ($1.10) EPS. Research analysts forecast that Intellia Therapeutics will post -3.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Farallon Capital Management LLC bought a new position in Intellia Therapeutics in the 3rd quarter valued at $10,486,000. Vanguard Group Inc. boosted its holdings in Intellia Therapeutics by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock valued at $190,744,000 after purchasing an additional 192,651 shares during the period. Jupiter Asset Management Ltd. purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at $23,519,000. Contrarius Group Holdings Ltd raised its position in shares of Intellia Therapeutics by 279.4% during the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after buying an additional 4,337,428 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in shares of Intellia Therapeutics by 68.0% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 494,468 shares of the company’s stock valued at $8,539,000 after buying an additional 200,081 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Intellia Therapeutics and reaffirmed a $25 price objective, signaling continued upside confidence. Intellia Therapeutics Price Target Cut to $25.00 by Analysts at HC Wainwright
• Positive Sentiment: The firm raised its FY2026 EPS estimate to a loss of $3.00 per share from a larger loss previously expected, suggesting some improvement in the earnings outlook. Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
• Positive Sentiment: HC Wainwright also lifted near-term estimates for Q2 2026 and Q3 2026, indicating analysts now expect slightly better operating performance than before. Intellia Therapeutics, Inc. First-Quarter Results Just Came Out: Here’s What Analysts Are Forecasting For This Year
• Neutral Sentiment: Other brokerage notes from Wells Fargo and Wedbush reportedly remained at Hold, suggesting the stock still has mixed analyst support.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.